- Home
- SUPN vs VCEL Comparison
SUPN vs VCEL Comparison
Compare SUPN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- VCEL
- Stock Information
- Founded
- SUPN 2005
- VCEL 1989
- Country
- SUPN United States
- VCEL United States
- Employees
- SUPN N/A
- VCEL N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUPN Health Care
- VCEL Health Care
- Exchange
- SUPN Nasdaq
- VCEL Nasdaq
- Market Cap
- SUPN 2.6B
- VCEL 2.1B
- IPO Year
- SUPN 2012
- VCEL 1997
- Fundamental
- Price
- SUPN $46.21
- VCEL $31.31
- Analyst Decision
- SUPN Buy
- VCEL Strong Buy
- Analyst Count
- SUPN 2
- VCEL 6
- Target Price
- SUPN $43.00
- VCEL $61.50
- AVG Volume (30 Days)
- SUPN 707.2K
- VCEL 613.1K
- Earning Date
- SUPN 11-03-2025
- VCEL 11-06-2025
- Dividend Yield
- SUPN N/A
- VCEL N/A
- EPS Growth
- SUPN 1411.53
- VCEL 2045.40
- EPS
- SUPN 1.14
- VCEL 0.13
- Revenue
- SUPN $665,125,000.00
- VCEL $249,119,000.00
- Revenue This Year
- SUPN $4.84
- VCEL $18.35
- Revenue Next Year
- SUPN $17.69
- VCEL $22.47
- P/E Ratio
- SUPN $40.24
- VCEL $234.44
- Revenue Growth
- SUPN 5.55
- VCEL 16.13
- 52 Week Low
- SUPN $29.16
- VCEL $30.33
- 52 Week High
- SUPN $46.79
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- SUPN 73.71
- VCEL 31.35
- Support Level
- SUPN $44.10
- VCEL $33.34
- Resistance Level
- SUPN $46.79
- VCEL $36.81
- Average True Range (ATR)
- SUPN 1.06
- VCEL 1.45
- MACD
- SUPN -0.17
- VCEL -0.31
- Stochastic Oscillator
- SUPN 85.92
- VCEL 14.79
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.